CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance

References

• Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12–23. doi:10.1038/nrclinonc.2013.197
   PubMed Web of Science ®Google Scholar
• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87. doi:10.1016/j.pathol.2017.09.006
   PubMed Web of Science ®Google Scholar
• Phelan JD, Young RM, Webster DE, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560(7718):387–391. doi:10.1038/s41586-018-0290-0
   PubMed Web of Science ®Google Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32. doi:10.1182/blood-2014-05-577189
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51–57. doi:10.1038/bmt.2015.213
   PubMed Web of Science ®Google Scholar
• Eyvazi S, Kazemi B, Dastmalchi S, et al. Involvement of CD24 in multiple cancer related pathways makes it an interesting new target for cancer therapy. Curr Cancer Drug Targets. 2018;18(4):328–336. doi:10.2174/1570163814666170818125036
   PubMed Web of Science ®Google Scholar
• Hough MR, Rosten PM, Sexton TL, et al. Mapping of CD24 and homologous sequences to multiple chromosomal loci. Genomics. 1994;22(1):154–161. doi:10.1006/geno.1994.1356
   Web of Science ®Google Scholar
• Lu S, Yao Y, Xu G, et al. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis. 2018;9(6):646. doi:10.1038/s41419-018-0681-z
   PubMed Web of Science ®Google Scholar
• Hüser L, Sachindra S, Granados K, et al. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. Int J Cancer. 2018;143(12):3131–3142. doi:10.1002/ijc.31609
   Web of Science ®Google Scholar
• Ono YJ, Tanabe A, Tanaka T, et al. Met signaling cascade is amplified by the recruitment of phosphorylated met to lipid rafts via CD24 and leads to drug resistance in endometrial cancer cell lines. Mol Cancer Ther. 2015;14(10):2353–2363. doi:10.1158/1535-7163.MCT-15-0187
   Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi:10.1182/blood-2017-03-769620
   PubMed Web of Science ®Google Scholar
• Chen GY, Brown NK, Zheng P, et al. Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity. Glycobiology. 2014;24(9):800–806. doi:10.1093/glycob/cwu068
   PubMed Web of Science ®Google Scholar
• Altevogt P, Sammar M, Hüser L, et al. Novel insights into the function of CD24: a driving force in cancer. Int J Cancer. 2021;148(3):546–559. doi:10.1002/ijc.33249
   PubMed Web of Science ®Google Scholar
• Ooki A, VandenBussche CJ, Kates M, et al. CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer. Br J Cancer. 2018;119(8):961–970. doi:10.1038/s41416-018-0291-7
   PubMed Web of Science ®Google Scholar
• Soltész B, Lukács J, Szilágyi E, et al. Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients. J Biotechnol. 2019;298:16–20. doi:10.1016/j.jbiotec.2019.03.018
   Web of Science ®Google Scholar
• Wang YC, Wang JL, Kong X, et al. CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation. Apoptosis. 2014;19(4):643–656. doi:10.1007/s10495-013-0949-9
   Web of Science ®Google Scholar
• Nagare RP, Sneha S, Sidhanth C, et al. Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours. Cancer Biomark. 2020;28(3):397–408. doi:10.3233/CBM-201463
   Web of Science ®Google Scholar
• Wang F, Flanagan J, Su N, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14(1):22–29. doi:10.1016/j.jmoldx.2011.08.002
   PubMed Web of Science ®Google Scholar
• Kersigo J, Pan N, Lederman JD, et al. A RNAscope whole mount approach that can be combined with immunofluorescence to quantify differential distribution of mRNA. Cell Tissue Res. 2018;374(2):251–262. doi:10.1007/s00441-018-2864-4
   Web of Science ®Google Scholar
• Barkal AA, Brewer RE, Markovic M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392–396. doi:10.1038/s41586-019-1456-0
   PubMed Web of Science ®Google Scholar
• Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPα immune checkpoint. Immunity. 2020;52(5):742–752. doi:10.1016/j.immuni.2020.04.011
   PubMed Web of Science ®Google Scholar
• Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492–1504. doi:10.1093/annonc/mdw217
   PubMed Web of Science ®Google Scholar
• Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67. doi:10.1182/blood-2017-06-741033
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Yin SS, Gao FH. Molecular mechanism of tumor cell immune escape mediated by CD24/Siglec-10. Front Immunol. 2020;11:1324. doi:10.3389/fimmu.2020.01324
   PubMed Web of Science ®Google Scholar
• Chen GY, Tang J, Zheng P, et al. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 2009;323(5922):1722–1725. doi:10.1126/science.1168988
   Web of Science ®Google Scholar
• Sammar M, Siwetz M, Meiri H, et al. Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface. Histochem Cell Biol. 2017;147(5):565–574. doi:10.1007/s00418-016-1531-7
   PubMed Web of Science ®Google Scholar
• Li Y, Zhou J, Zhuo Q, et al. Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression. Cancer Manag Res. 2019;11:7123–7134. doi:10.2147/CMAR.S210568
   PubMed Web of Science ®Google Scholar
• Ding Y, Guo Z, Liu Y, et al. The lectin Siglec-G inhibits dendritic cell cross-presentation by impairing MHC class I-peptide complex formation. Nat Immunol. 2016;17(10):1167–1175. doi:10.1038/ni.3535
   PubMed Web of Science ®Google Scholar
• Zhang P, Lu X, Tao K, et al. Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma. J Surg Res. 2015;194(1):107–113. doi:10.1016/j.jss.2014.09.035
   PubMed Web of Science ®Google Scholar
• Salnikov AV, Bretz NP, Perne C, et al. Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. Br J Cancer. 2013;108(7):1449–1459. doi:10.1038/bjc.2013.102
   Web of Science ®Google Scholar